期刊文献+

甲亢性骨质疏松的研究进展 被引量:16

Research Progress of Osteoporosis in Patients with Hyperthyroidism
下载PDF
导出
摘要 甲状腺功能亢进症(甲亢)引起的继发性骨质疏松是继糖尿病性骨质疏松之后又一研究热点。本文旨在对甲亢性骨质疏松的研究进展进行综述,结果表明甲亢是继发性骨质疏松的常见病因,促甲状腺激素(TSH)的降低可能独立于甲状腺激素(TH)参与其中。多数临床研究显示甲亢可致净骨量丢失,骨密度(BMD)下降致骨质疏松,甚至可增加未来骨折的风险。积极的抗甲亢及补钙辅助治疗是目前较确切有效对抗甲亢性骨质疏松的策略。甲亢性骨质疏松的发病机制及临床研究方兴未艾,未来需要更多更高质量的研究予以探讨。 Hyperthyroidism is a common cause of secondary osteoporosis. The decrease of thyroid stimulating hormone may be independent of thyroid hormone and takes part in the process of secondary osteoporosis separately. Most clinical studies have shown that hyperthyroidism can cause the net bone loss, and the decreased bone mineral density induces the osteoporosis, and even furthermore increases the risk of fractures. Positive anti - hyperthyroidism treatment assisted with adjuvant calcium therapy is the most effective strategy against osteoporosis in patients with hyperthyroidism. Clinical research on the pathogenesis of osteoporosis in patients with hyperthyroidism has just risen and more high quality researches will be need in the future.
出处 《中国全科医学》 CAS 北大核心 2017年第25期3187-3190,3194,共5页 Chinese General Practice
基金 国家自然科学基金资助项目(81273518)
关键词 甲状腺功能亢进症 骨质疏松 骨密度 骨折 综述 Hyperthyroidism Osteoporosis Bone density Fractures, bone Review
  • 相关文献

参考文献4

二级参考文献57

  • 1范丽凤,张小群,陆菊明,张高魁.皮质醇增多症患者的生活质量及其影响因素[J].中国临床康复,2005,9(15):30-32. 被引量:2
  • 2李思,薛延,王洪复.骨质疏松鉴别诊断与治疗[M].北京:人民卫生出版社,2005:471.
  • 3Udayakumar N,Chandrasekaran M,Rasheed MH,et al.Evaluation of bone mineral density in thyrotoxicosis[J].Singapore Med J,2006,47 (11):947-950.
  • 4Amato G,Mazziotti G,Sorvillo F,et al.High serum osteoprotegerin levels in patients with hyperthyroidism:effect of medical treatment[J].Bone,2004,35(3):785-791.
  • 5Safi S,Hassikou H,Hadri L,et al.Evaluation of bone mineral density in hyperthyroid patients before and after medical therapy[J].Ann Endocrinol (Paris),2006,67(1):27-31.
  • 6Karga H,Papapetrou PD,Korakovouni A,et al.Bone mineral density in hyperthyroidism[J].Clin Endocrinol (Oxf),2004,61 (4):466-472.
  • 7Drake MT,Clarke BL,Khosla S.Bisphosphonates:mechanism of action and role in clinical practice[J].Mayo Clin Proc,2008,83(9):1032-1045.
  • 8Lupoli G,Nuzzo V,Di-Carlo C,et al.Effects of alendronate on bone loss in pre-and postmenopausal hyperthyroid women treated with methimazole[J].Gynecol Endocrinol,1996,10 (5):343-348.
  • 9Lupoli G,Fittipaldi MR,Fonderico F,et al.Methimazole versus Methimazole and diphosphonates in hyperthyroid and osteoporotic patients[J].Minerva Endocrinol,2005,30 (2):89-94.
  • 10Majima T,Komatsu Y,Doi K,et al.Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves'disease[J].J Bone Miner Metab,2006,24 (2):105-113.

共引文献11

同被引文献184

引证文献16

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部